CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system, commonly known as cytokine storm.
https://cytoagents.com/
https://cytoagents.com/
Investors 3
Mentions in press and media 7
| Date | Title | Description |
| 26.09.2024 | CytoAgents: Cytokine Release Syndrome Treatment Company Receives Third Grant From NIH | CytoAgents – a clinical-stage biotechnology company dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS) – announced that it has been awarded a $2 million National Institutes of Health (NIH) grant, the ... |
| 14.06.2021 | Meet the 7 life science startups of AlphaLab Health’s inaugural accelerator cohort | Seven promising life science startups started off 2020 with a shot of support from two of the region’s health and economic development-minded orgs. Launched in September 2020, AlphaLab Health is an initiative of Innovation Works, which also... |
| 05.04.2021 | Seven early-stage health companies selected for Pittsburgh's inaugural AlphaLab Health accelerator cohort | Dr. Jeffrey Cohen, Chief Physician Executive for Community Health and Innovation at Allegheny Health Network (AHN) “This is a unique collaboration between two world-class organizations, and the first cohort marks a key milestone for our par... |
| 11.07.2020 | Broad Street Angels Hears Pitches from 3 Female CEO Entrepreneurs | Philadelphia, PA – Open for business and selecting high growth companies to pitch its members for investment, the Broad Street Angels held its July investment meeting with a lineup of 3 dynamic female CEO led companies. |
| 13.05.2020 | Pittsburgh has long been a life sciences engine. Now it’s at the forefront of COVID-19 vaccine efforts | If Dr. Louis Falo and his team at the University of Pittsburgh are successful, the same medical school that produced the vaccine that ended polio could produce the vaccine that ends COVID-19. “It’s great to be in this environment, with this... |
| - | CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm | PITTSBURGH--(BUSINESS WIRE)--Mar 10, 2021-- CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release ... |
| - | CytoAgents | - |